MedTrace Logo

Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine

NCT01224613 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2011-06-15

No results posted yet for this study

Summary

The purpose of this study is to compare the immunogenicity and reactogenicity of self-administered intradermal influenza vaccine (Intanza)to nurse-administered.

Conditions

Interventions

BIOLOGICAL

Intanza

0.1 mL of Intanza intradermally at visit # 1

BIOLOGICAL

Intanza

0.1 mL of Intanza intradermally at visit #1

Sponsors & Collaborators

  • IWK Health Centre

    collaborator OTHER

  • MCM Vaccines B.V.

    collaborator INDUSTRY

  • Mount Sinai Hospital, Canada

    collaborator OTHER

  • Dalhousie University

    lead OTHER

Principal Investigators

  • Shelly McNeil, MD · Canadian Center for Vaccinology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-01-31
Completion
2011-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224613 on ClinicalTrials.gov